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Passive immunization does not provide 
protection against experimental infection 
with Mycoplasma haemofelis
Sarah Sugiarto1,2, Andrea M. Spiri1,2, Barbara Riond1,2, Marilisa Novacco1,2, Angelina Oestmann1,2, 
Luisa H. Monteiro de Miranda4, Marina L. Meli1,2, Felicitas S. Boretti3, Regina Hofmann‑Lehmann1,2† 
and Barbara Willi1,3*†
Abstract 
Mycoplasma haemofelis (Mhf) is the most pathogenic feline hemotropic mycoplasma. Cats infected with Mhf that clear 
bacteremia are protected from Mhf reinfection, but the mechanisms of protective immunity are unresolved. In the 
present study we investigated whether the passive transfer of antibodies from Mhf‑recovered cats to naïve recipient 
cats provided protection against bacteremia and clinical disease following homologous challenge with Mhf; moreo‑
ver, we characterized the immune response in the recipient cats. Ten specified pathogen‑free (SPF) cats were trans‑
fused with pooled plasma from cats that had cleared Mhf bacteremia; five control cats received plasma from naïve 
SPF cats. After homologous challenge with Mhf, cats were monitored for 100 days using quantitative PCR, hematol‑
ogy, blood biochemistry, Coombs testing, flow cytometry, DnaK ELISA, and red blood cell (RBC) osmotic fragility (OF) 
measurement. Passively immunized cats were not protected against Mhf infection but, compared to control cats, 
showed significantly higher RBC OF and B lymphocyte (CD45R/B220+) counts and occasionally higher lymphocyte, 
monocyte and activated CD4+ T lymphocyte (CD4+CD25+) counts; they also showed higher bilirubin, total protein 
and globulin levels compared to those of control cats. At times of peak bacteremia, a decrease in eosinophils and 
lymphocytes, as well as subsets thereof (B lymphocytes and CD5+, CD4+ and CD8+ T lymphocytes), and an increase 
in monocytes were particularly significant in the passively immunized cats. In conclusion, passive immunization does 
not prevent bacteremia and clinical disease following homologous challenge with Mhf, but enhances RBC osmotic 
fragility and induces a pronounced immune response.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Hemotropic mycoplasmas (hemoplasmas) are non-
cultivable epierythrocytic bacteria that infect a variety 
of mammalian species worldwide [1]. In recent years, 
hemoplasmas have attracted scientific attention due to 
their host diversity and pathogenic potential [1]. The 
main pathogenic feature of hemoplasmas is hemoly-
sis, and clinical signs such as lethargy, anorexia, pale 
mucosal membranes, pyrexia, jaundice and pigmenturia 
may be present in severely affected animals [1]. Reports 
of hemoplasma infections in humans emphasize the need 
to characterize these agents in more detail [2–7]. Feline 
hemoplasmas can thereby serve as a model because of 
their extensive molecular and clinical characterization 
within this group of organisms.
Feline hemoplasmas comprise at least three differ-
ent species: Mycoplasma haemofelis (Mhf), “Candidatus 
Mycoplasma haemominutum” (CMhm) and “Candidatus 
Mycoplasma turicensis” (CMt) [8–10]. Concurrent infec-
tions with two or three hemoplasma species have been 
documented [11–14], suggesting that no immunologi-
cal cross-protection exists between the feline hemoplas-
mas, which has recently been experimentally confirmed 
[15]. Mhf is the most pathogenic of the three feline 
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hemoplasma species and can induce severe hemolytic 
anemia, which is potentially fatal if left untreated. In con-
trast, the other two feline hemoplasmas may induce mild 
anemia, and the infection often remains subclinical [16].
The natural route of hemoplasma transmission 
between cats is still unresolved, but aggressive interac-
tions and blood-sucking arthropods have mainly been 
implicated [17–19]. For experimental transmission, the 
intraperitoneal, intravenous or subcutaneous inoculation 
of hemoplasma-containing blood has been successful [10, 
19–21]. Recently, a low-dose infection model for Mhf 
that aimed to more accurately mirror the natural trans-
mission of hemoplasmas was developed [22].
Different antibiotic regimens reduce hemoplasma 
blood loads and alleviate clinical signs but, so far, no 
treatment protocol has successfully and consistently 
cleared feline hemoplasma infections [21, 23–26]. This 
limitation emphasizes the need to further investigate 
protective immune mechanisms against these agents. 
Recently, cats that were experimentally infected with Mhf 
or CMt and overcame bacteremia were shown to be pro-
tected from reinfection with the same hemoplasma spe-
cies [27, 28]. A study by Novacco et al. [27] suggested a 
significant role for the humoral immune response in 
protecting against CMt reinfection: nine out of the ten 
cats that were protected from reinfection showed inter-
mediate to high antibody levels against CMt before chal-
lenge. Furthermore, a transient decrease in antibody 
levels was observed in the protected cats immediately 
after attempted reinfection, which could be due to the 
binding of antibodies to the inoculated antigens. In the 
early phase after re-challenge, compared with the con-
trol group, the protected cats exhibited significantly 
higher IL-4/IL-12 ratios and CD4+ T lymphocyte counts 
and a pronounced eosinophilia. Therefore, the authors 
concluded that an early Th2 immune response, prior 
to the onset of bacteremia, is beneficial for protection 
against CMt reinfection [27]. This result was not found 
in the study by Hicks et al. [28], where an early increase 
in the pro-inflammatory cytokines tumor necrosis 
factor-α (TNF-α) and interleukin-6 (IL-6) was observed 
in cats protected from Mhf reinfection. Furthermore, 
the immune response seemed to be skewed towards a 
Th1 response after primary Mhf infection, whereas a 
switch from an initial Th1 to a delayed Th2 response was 
observed after primary CMt infection [27, 28]. These 
results suggest that cats respond to infection by differ-
ent feline hemoplasma species with different immune 
mechanisms.
Important data on the immune response elicited by 
hemoplasma infection have been provided by previous 
studies [27, 28], but the mechanisms that confer protec-
tion against re-infection have yet to be clarified. Passive 
immunization transfers humoral immunity to a non-
immune individual in the form of antibodies and allows 
the protective role of antibodies in the absence of cel-
lular immune mechanisms to be assessed. The present 
study aimed to investigate whether the passive transfer 
of antibodies from Mhf-recovered to naïve recipient cats 
induced partial or complete protection against bactere-
mia and clinical disease following homologous challenge 
with Mhf. Different parameters addressing the humoral 
and cellular immune response were monitored in pas-
sively immunized and control cats.
Materials and methods
Animals
In the main experiment, 15 4-month-old male specified 
pathogen-free (SPF) cats from Liberty Research, Inc. 
(Waverly, New York, USA) were used as recipient cats. 
Five adult SPF cats served as blood donors: three of these 
cats had overcome a previous Mhf infection (HBU2, 
HBZ2 and HCD2) [28], while two cats were naïve adult 
SPF cats (GCN5 and JCR4). Moreover, in a pre-exper-
iment, a 2-year-old male castrated SPF cat (HCC4) was 
used. All cats were housed in groups in a confined uni-
versity facility under ethologically and hygienically ideal 
conditions [29]. All experiments were approved by the 
veterinary office of the Canton of Zurich (TVB 92/2014) 
and were conducted in accordance with Swiss laws.
Fifty days prior to plasma transfusion and experimental 
infection, the SPF status of all the cats was confirmed by 
testing for the absence of infection with feline hemoplas-
mas, feline calicivirus, feline herpesvirus-1, feline corona-
virus, feline leukemia and feline immunodeficiency virus, 
as well as Bartonella henselae and Chlamydia felis, as 
recently described [19, 30]; the absence of Mhf infection 
was again confirmed by real-time TaqMan® quantitative 
(q)PCR [12] on day 0 prior to plasma transfusion and 
Mhf inoculation. All donor cats and the cat from the pre-
experiment were blood-typed using a commercial immu-
nochromatography technique (Feline Lab Test A  +  B, 
Alvedia, France). The recipient cats had been blood-
typed by Liberty Research, Inc. (Waverly). A standard 
saline-agglutination cross-matching procedure was per-
formed to ascertain the compatibility of transfusion [31].
Plasma preparation and transfusion
For passive immunization, a total of 118  mL of plasma 
was collected from the three cats that had overcome pre-
vious Mhf infection (HBU2, HBZ2 and HCD2) [28]. The 
plasma was collected from these cats on day 538 post 
Mhf inoculation. HBU2 had cleared the infection with-
out treatment, whereas HBZ2 and HCD2 had received 
antibiotic treatment to clear the infection (HBZ2: 
10  mg/kg/day doxycycline for 44  days; HCD2: 10  mg/
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kg/day doxycycline for 27  days, followed by 2  mg/kg/
day marbofloxacin for 23  days); in the latter two cats, 
antibiotic treatment was stopped 59–129  days prior to 
plasma collection. All cats tested negative for Mhf for at 
least eight consecutive weeks following antibiotic treat-
ment and prior to the plasma collection, as determined 
using weekly collected blood samples that were analyzed 
in triplicate with a Mhf-specific qPCR assay [12]. For 
plasma transfusion of the control cats, a total of 70 mL of 
plasma from two adult naïve SPF cats (GCN5 and JCR4) 
was collected. Prior to plasma collection, the two cats 
were confirmed to be negative for all three feline hemo-
plasmas using qPCR [12] and to be free from all com-
monly known feline pathogens, as described [19].
For plasma preparation, whole blood was collected 
from the donor cats from the jugular vein under short-
duration general anesthesia (10  mg/kg ketamine, Nar-
ketan®, Vétoquinol AG, Belp, Switzerland; 0.1  mg/kg 
midazolam, Dormicum®, Roche Pharma AG, Reinach, 
Switzerland); the blood was anti-coagulated with acid-
citrate-dextrose (ACD) to a final concentration of 3.5%. 
Plasma was separated from RBCs by centrifugation at 
3000g for 10  min and stored at −80  °C until use. Prior 
to transfusion, the plasma was thawed, pooled (pool A: 
plasma from the Mhf-recovered cats HBU2, HBZ2 and 
HCD2; pool B: plasma from the naïve SPF cats GCN5 
and JCR4), and filtered through a 0.22 µm pore-size fil-
ter (JET BIOFIL, Madrid, Spain), and 9 mL aliquots were 
prepared. Before freezing and after thawing and filtra-
tion, the plasma was tested in triplicate with a Mhf-spe-
cific qPCR assay for the absence of Mhf organisms [12].
For the plasma transfusion, all recipient cats were put 
under short-duration general anesthesia (10 mg/kg keta-
mine, Narketan®, Vétoquinol AG; 0.1 mg/kg midazolam, 
Dormicum®, Roche Pharma AG) and 9  mL of whole 
blood was collected for baseline analysis and to pre-
vent circulatory volume overload. The plasma was pre-
warmed to 38  °C and intravenously administered over 
a duration of 30  min using standard blood transfusion 
sets (HEMO-NATE®, 18 Micron, Utah Medical Prod-
ucts, Inc., Utah, USA). During transfusion, the cats were 
closely monitored for transfusion reactions.
Experimental design
In the pre-experiment, an adult naïve SPF cat (HCC4) 
was intravenously transfused with a 10  mL aliquot of 
plasma pool A that was later used for the passive immu-
nization of the cats in group A. After the transfusion, 
weekly blood samples were collected from the cat for 
23 weeks and analyzed using Mhf-specific qPCR [12].
For the main experiment, the recipient cats were 
assigned to two groups: group A (n = 10, passive immu-
nization, cats DHR1, DHR2, JHW1, JHW2, JHW4, JHW5, 
JHX1, JHX2, JHZ1 and JIC1) and group B (n = 5, control 
group, cats DHP1, DHT1, JHV1, JHW3 and JIC2). The 
cats of each group were housed together during and after 
the end of the study period. On day 0, plasma transfusion 
was performed, and the cats were experimentally inocu-
lated with Mhf. For the passive immunization, each cat 
in group A was transfused with a 9 mL aliquot of plasma 
pool A. Each cat in group B was transfused with a 9 mL 
aliquot of plasma pool B. Ten minutes after the comple-
tion of the transfusion, all cats in groups A and B were 
inoculated with Mhf by a subcutaneous injection of 10 µL 
of 20% dimethyl sulfoxide (DMSO)-preserved blood con-
taining 103 copies of Mhf diluted with 90 µL of phosphate-
buffered saline (PBS), as previously described [22]. An 
aliquot of the same Mhf inoculum was used to infect the 
recipient cats in this study that had been used to infect the 
plasma donor cats (HBU2, HBZ2 and HCD2) in a previ-
ous study [28]. Clinical condition, body temperature and 
body weight were recorded, and blood samples collected 
prior to plasma transfusion and Mhf inoculation (day 0), 
twice weekly post inoculation (pi) until week 7 and weekly 
thereafter up to day 100 pi.; an additional blood collection 
to measure red blood cell (RBC) osmotic fragility (OF) 
was performed on day 179 pi because RBC OF was still 
increased compared with baseline values in several cats of 
group A and B at day 100 pi. All samples were collected 
without anesthesia, with the exception of the samples 
collected at day 0. Samples for PCR analysis and serol-
ogy were stored at −80 °C until analysis. Flow cytometry, 
hematology, blood biochemistry, Coombs tests and RBC 
OF assays were carried out within 4 h of blood collection.
Hematology and blood biochemistry
Hematological parameters were determined on day 0, 
twice weekly pi until week 7 and weekly thereafter up 
to day 100 pi on a Sysmex XT-2000iV instrument (Sys-
mex Corporation, Kobe, Japan), as previously described 
[32]. White blood cell differential analysis was confirmed 
using manual evaluation of Wright-Giemsa stained 
blood smears. Severity of anemia was defined as mild 
(25–33%), moderate (15–25%) and severe (<15%). Bili-
rubin, total protein and albumin concentrations were 
measured on day 0, on days 3 and 7 pi and weekly there-
after until day 100 pi using a Cobas Integra 800 system 
(Roche Diagnostics, Rotkreuz, Switzerland). Globulin 
values were calculated by subtracting the albumin value 
from the total protein concentration. Reference intervals 
(mean ± standard deviation, SD) for PCV and total pro-
tein concentrations for kittens of 16 and 30 weeks of age 
were obtained from the literature [33]. Because biliru-
bin concentrations reach adult values after 1 week of age 
[33], the laboratory’s device-specific reference interval 
was used for this parameter.
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RBC OF and direct Coombs testing
RBC OF was determined on day 0 and on days 21, 100 
and 179 pi using a published protocol [10]. The refer-
ence interval was determined in nine healthy cats dur-
ing a previous study (50% hemolysis in NaCl 0.50–0.57% 
w/v) [10]. Direct Coombs tests were performed on day 0 
and on days 21 and 100 pi. RBCs from EDTA-anticoagu-
lated blood samples were washed, diluted in NaCl 0.9% 
w/v solution and incubated for 1  h at 37  °C with feline 
antiglobulin reagent (MP Biomedicals, LLC., Solon, 
Ohio, USA) in dilutions ranging from 1:2 to 1:10240, as 
described [10]. Agglutination in dilutions of ≥1:8 was 
defined as positive.
Quantification of bacterial loads
Quantification of Mhf blood loads by qPCR was per-
formed on day 0, twice weekly pi until week 7 and weekly 
thereafter up to day 100 pi. Total nucleic acid (TNA) 
was extracted from 100  μL of EDTA anti-coagulated 
blood using the MagNa Pure LC (Roche Diagnostics AG, 
Rotkreuz, Switzerland) and the MagNa Pure LC TNA 
Isolation Kit (Roche Diagnostics) following the manu-
facturer’s instructions. TNA was eluted in 100 µL elution 
buffer and stored at −80  °C until use. With each batch 
of extraction, a negative control consisting of 200 µL of 
phosphate-buffered saline (PBS) was used to monitor for 
cross-contamination. All TNA samples were tested with 
a Mhf-specific qPCR assay to detect and quantify Mhf as 
previously described [12]. For absolute quantification, 
tenfold serial dilutions of a standard plasmid were used 
as described [12]. Positive and negative controls were 
included in each PCR run.
Serology
Antibodies against the recombinant DnaK protein of Mhf 
were measured on day 0, on days 3 and 7 pi and weekly 
thereafter until day 100 pi using a previously described 
ELISA [20]. The serum was diluted 1:200, and 50  ng of 
recombinant protein per well was used as described [20]. 
All samples collected from one cat were measured on the 
same plate, and all plates were antigen coated within the 
same batch. Absorbance was measured at a wavelength of 
415 nm (OD415) using a SpectraMax Plus 348 microplate 
spectrophotometer (Molecular Devices, Sunnyvale, CA, 
USA). An OD415  ≤  0.33 was defined as negative based 
on DnaK ELISA results obtained from 20 SPF cats, as 
described [20].
Flow cytometry
Flow cytometric analysis was performed on day 0 and 
on days 3, 7, 14, 21, 28, 42, 56, 70 and 98 pi. Three dif-
ferent staining combinations of primary antibodies were 
used: (1) Fluorescein isothiocyanate (FITC)-conjugated 
mouse anti-feline CD5 antibody (f43, Southern Biotech, 
Allschwil, Switzerland); (2) an R-phycoerythrin (RPE)-
conjugated mouse anti-feline CD4 antibody (Vpg34, AbD 
Serotec, Puchheim, Germany) and a FITC-conjugated 
mouse anti-feline CD25 antibody; and (3) a FITC-conju-
gated mouse anti-feline CD8 antibody (fCD8, Southern 
Biotech) and a RPE-conjugated rat anti-mouse CD45R/
B220 antibody (RA3-6B2, AbD Serotec). CD5 is a marker 
for feline T lymphocytes [34], and CD4+- and CD8+-
positive T lymphocytes represent helper and cytotoxic 
T lymphocytes, respectively [35]. CD4+CD25+ T lym-
phocytes represent activated CD4+ T lymphocytes, and 
CD45R/B220 antibody was used to identify B lympho-
cytes [36, 37].
Prior to the start of the experiment, the antibodies 
were titrated for optimal dilution as follows: CD4 and 
CD8, 1:50 dilution; CD25 and CD5, 1:100 dilution; and 
CD45R/B220, undiluted. A 50 µL aliquot of EDTA anti-
coagulated blood was incubated with 5 µL of the afore-
mentioned antibodies. To rule out non-specific binding, 
isotype control antibodies (RPE-conjugated Mouse IgG1 
and FITC-conjugated Mouse IgG1, AbD Serotec) and 
unstained blood samples from each cat were used as neg-
ative controls. Blood samples were stained according to 
published protocols [27, 28].
Flow cytometry was performed using a guava easy-
Cyte™ 8HT Flow Cytometer (Millipore, Darmstadt, 
Germany) using the GuavaSoft 2.5 software. Gates rep-
resenting the lymphocyte population were set based on 
forward and side scatter, and 10 000 events were acquired 
for each sample. The absolute number of each lympho-
cyte subset was calculated by multiplying the absolute 
lymphocyte number from hematology by the subset per-
centage as previously published [38].
Statistics
Up to 22 different parameters per cat were statistically 
analyzed using Analyse-it® for Microsoft Excel version 
1.0.5.0 (Analyse-it Software, Ltd., Leeds, UK) and Graph-
Pad Prism 5.03 (GraphPad Software, Inc., CA, USA). 
The Mann–Whitney U test (pMWU) was used to com-
pare the two groups A and B at each time point. One cat 
(JHW3) in group B stayed PCR-negative and seronega-
tive throughout the 100-day study period. To investigate 
whether significant differences observed between groups 
A and B were related to the inclusion of this cat, the 
Mann–Whitney U tests were repeated without the data 
of this cat for all significant parameters. The results from 
these analyses were reported if they differed from the 
original results including cat JHW3. Friedman’s test (pF) 
followed by Dunn’s post test (pD) was used to analyze the 
parameters over time when more than two time points 
were considered. Multiplicity adjusted P values for each 
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comparison in a family of comparisons were computed. 
Fisher’s exact test was used to determine significant dif-
ferences of proportions. P values <0.05 were considered 
significant.
Results
All donor cats, the cat from the pre-experiment and all 
recipient cats were confirmed to be blood type A. Cross-
matching revealed no incompatibilities between the 
donor cats, the cat of the pre-experiment and the recipi-
ent cats. All plasma samples used for transfusion tested 
Mhf PCR-negative.
Pre‑experiment
The adult cat (HCC4) transfused with an aliquot of 
plasma pool A during the pre-experiment tested Mhf 
PCR-negative in each of the samples collected dur-
ing the 23 weeks after the transfusion (data not shown). 
The cat stayed clinically healthy throughout the entire 
experiment.
Passive immunization does not provide protection 
against Mhf bacteremia
Prior to plasma transfusion and experimental infection 
(day 0), all cats in both groups tested Mhf PCR-nega-
tive. All cats in groups A and B became Mhf PCR-pos-
itive within 7–31  days and 7–38  days pi, respectively 
(Figures 1A and B), except for one cat (JHW3) in group 
B. Cat JHW3 remained PCR-negative throughout the 
100-day follow-up period (Figure  1B) but became Mhf 
PCR-positive after the end of the experiment (day 154 
pi, data not shown). Peak hemoplasma loads (group A: 
2.3 × 108–1.7 × 109 copies/mL blood; group B 1.8 × 108–
8.6 × 108 copies/mL blood) were reached between days 
17 and 49 pi in group A and days 17 and 63 pi in group 
B. There was no significant difference in Mhf blood loads 
between the two groups during the 100-day follow-up 
period, except for day 100 pi, when group A showed 
significantly higher Mhf blood loads (pMWU  =  0.0280; 
Figure  1C); this difference was not significant when the 
PCR-negative cat JHW3 in group B was excluded from 
the analysis (pMWU = 0.0759).
Anti‑DnaK antibody levels were higher in passively 
immunized cats than in control cats in the first days 
after plasma transfusion
The cats in both groups tested negative in the DnaK 
ELISA (defined as an OD415 ≤ 0.33) prior to the plasma 
transfusion (Figures  2A  and B). After passive immuni-
zation and subsequent infection, group A cats showed 
slightly but significantly higher DnaK ELISA OD415 val-
ues at days 3, 7 and 14 pi compared with the OD415 val-
ues of cats in group B (pMWU < 0.05; Figure 2C). From day 
21 until day 100 pi, no significant difference in the DnaK 
ELISA OD415 values was evident between the two groups. 
When cat JHW3 was excluded from the analyses, the 
anti-DnaK antibody level in cats in group A was still sig-
nificantly higher early after passive immunization (days 3 
and 7 pi, PMWU < 0.05), but not at day 14 pi and thereafter 
until day 100 pi when compared to cats in group B. There 
was no significant difference in the time of seroconver-
sion (OD415 > 0.33) between the two groups; cats in both 
groups, A and B, seroconverted between days 21 and 
49 pi, with the exception of cat JHW3 (group B), which 
did not develop anti-Mhf DnaK antibodies throughout 
the study (Figure  2B). Two other cats (JHW2, group A, 
and JHV1, group B) were seronegative (OD415 ≤ 0.33) by 
the end of the experiment (Figure 2B); one of these cats 
(JHW2) was treated with doxycycline between days 28 
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Figure 1 Mhf blood loads in passively immunized and control 
cats after Mhf infection. Mhf blood loads (y‑axis, as log copies/mL 
of blood) of individual cats in group A (A) and B (B) and mean (+SD) 
Mhf blood loads in group A and B (C) are shown during the 100 days 
pi. Because of the logarithmic scale, only the positive SD is shown 
in (C). All cats were subcutaneously inoculated with Mhf at day 0. 
Significant differences between groups are indicated with asterisks 
(pMWU < 0.05). Cat JHW3 in group B stayed PCR‑negative throughout 
the 100‑day follow‑up period but turned PCR‑positive at day 154 pi 
(not shown).
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to 42 pi because of a pronounced decrease in packed cell 
volume (PCV) to 21% (day 28 pi, see below).
No difference in PCV and clinical signs between the 
passively immunized and control cats
Seven out of ten cats in group A became moderately 
anemic (PCV between 15 and 25%) at days 28 to 56 pi 
(Figure 3A). In group B, one cat showed moderate anemia 
(PCV 25%) and one cat severe anemia (PCV 10%) at days 
35 and 26 pi, respectively (Figure  3B). The lowest PCV 
observed during the study was found for cat DHT1 (PCV 
10%, 26 days pi) in group B. There was no significant dif-
ference in the mean PCV values between the two groups 
(Figure 3C). There was a significant change in PCV over 
time for both groups (group A, pF  <  0.0001; group B, 
pF = 0.0003); PCV values of the cats were higher towards 
the end of the study period when compared to the first 
weeks pi (Figures 3A and B). This finding may be attrib-
uted to the increasing age of the cats; reference intervals 
of PCV (±SD, %) were reported to increase from the age 
of 16 weeks (34.9 ± 1.1) to 30 weeks (37.1 ± 3.4) [33].
Three cats in group A (cats JHW2, JHW4 and JHZ1) 
and two cats in group B (cats DHT1 and JHV1) devel-
oped elevated body temperature >39.5  °C during the 
course of the experiment: JHV1 at day 12 pi, JHW4 at day 
23 pi, DHT1 at day 26 pi, JHW2 at day 28 pi and JHZ1 
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Figure 2 Anti-DnaK antibody response in passively immu-
nized and control cats. Anti‑DnaK antibody levels (y‑axis, as OD415 
values) of individual cats in group A (A) and B (B) and mean (±SD) 
anti‑DnaK antibodies in group A and B (C) during the 100 days 
pi. All cats were subcutaneously inoculated with Mhf at day 0. An 
OD415 value of 0.33 is indicated by a dotted line and represents the 
threshold for seropositivity. Significant differences between groups 
are indicated with asterisks (pMWU < 0.05).
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Figure 3 Course of PCV in passively immunized and control 
cats. PCV values (y‑axis, as percentage) of individual cats in group A 
(A) and B (B) and mean (±SD) PCV values in group A and B (C) during 
the 100 days pi are shown. All cats were subcutaneously inoculated 
with Mhf at day 0. There was a significant change in PCV over time 
in cats in group A (pF < 0.0001, lower values at days 0, 31, 35 and 56 
compared with days 21, 91, 98 and 100 pi, pD < 0.05) and group B 
(pF = 0.0003, significantly lower values at day 0 compared with days 
91, 98 and 100 pi, pD < 0.05).
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at day 48 pi. In addition, apathy, anorexia and weakness 
were observed in three cats in group A (JHW2 and JIC1 
at day 28 pi; and JHX2 at day 36 pi) and in one cat in 
group B (DHT1 at day 26 pi).
Three cats necessitated oral antibiotic treatment with 
doxycycline (10  mg/kg/day, Supracycline, Grünenthal 
GmbH, Mitlödi, Switzerland) for 14–16  days. The deci-
sion to treat the cats was based on the presence of severe 
anemia (group A: DHT1, PCV of 10%, day 26 pi) or a 
pronounced decrease in PCV within 24  h (JHW2, PCV 
of 21%, day 28 pi; JHX2, PCV of 15%, day 36 pi). All three 
cats showed clinical signs (apathy, anorexia, weakness 
and fever) when the treatment was initiated.
Higher RBC OF in passively immunized than in control cats
At day 0, RBC OF was significantly lower in cats in group 
A when compared to cats in group B (pMWU =  0.0127), 
but mean RBC OF of both groups remained within the 
reference interval (group A and B, 50% hemolysis in NaCl 
0.54 and 0.56% w/v, respectively; reference interval, 50% 
hemolysis in NaCl 0.50–0.57% w/v, Figure  4C). There-
after, at days 21 and 100 pi, RBC OF was significantly 
higher in cats in group A compared to cats in group B 
(pMWU < 0.05; Figure 4C). When cat JHW3 was excluded 
from the analyses, there was no longer a significant dif-
ference between the groups on day 100 pi. Remark-
ably, compared with baseline values, RBC OF was still 
increased in several cats in groups A and B at day 100 
pi (Figures  4A  and B ); therefore, one further measure-
ment was obtained at day 179 pi. RBC OF significantly 
changed during the course of infection only in cats in 
group A (pF = 0.0004, Figure 4A). The RBC OF reached 
maximal values at day 21 pi in eight out of ten animals in 
group A (range, 50% hemolysis in NaCl 0.63–0.79% w/v) 
and at day 100 pi in cat JHZ1 (50% hemolysis in NaCl 
0.62% w/v) and at day 179 pi in cat JHW1 (50% hemoly-
sis in NaCl 0.66% w/v; Figure 4A). Cat JHW3 in group B, 
which turned Mhf PCR-positive only after the end of the 
experiment (day 154 pi), showed a pronounced increase 
in relative RBC OF at the time of Mhf bacteremia (50% 
hemolysis in NaCl 0.75% w/v, day 179 pi; reference inter-
val, 50% hemolysis in NaCl 0.50–0.57% w/v; Figure 4B). 
All cats in both groups tested negative in the direct 
Coombs test at all time points (data not shown).
Decrease in lymphocyte and eosinophil counts 
and increase in monocyte counts coinciding with maximal 
Mhf bacteremia
Cats in both groups showed an increase in leukocyte 
counts immediately after infection, followed by a sig-
nificant decrease, with the nadir being reached three to 
four weeks pi (data not shown). There was no significant 
difference in leukocyte counts between the two groups 
during the 100-day follow-up period. The lymphocyte 
cell counts showed an initial increase followed by a sig-
nificant decrease, with the nadir reached at day 21 pi, 
coinciding with the onset of peak bacteremia in cats in 
group A (pF  <  0.0001, Figure  5A); this pattern was less 
pronounced in cats in group B (pF = 0.0033, Figure 5A). 
Furthermore, compared with cats in group B, cats in 
group A had significantly higher blood lymphocyte 
counts at days 3 and 35 pi (pMWU  <  0.05), as well as a 
tendency for higher counts at day 42 pi (pMWU = 0.0553, 
Figure  5A). When cat JHW3 was excluded from the 
analyses, the lymphocyte cell counts tended to be 
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Figure 4 Course of RBC OF in passively immunized and control 
cats. RBC OF (y‑axis, as percentage (w/v) NaCl concentration with 
50% hemolysis) of individual cats in group A (A) and B (B) at day 0 
and at days 21, 100 and 179 pi and mean (±SD) RBC OF in group A 
and B (C) are shown. All cats were subcutaneously inoculated with 
Mhf at day 0. Significant differences between groups are indicated 
with asterisks (pMWU < 0.05). The reference interval for RBC OF based 
on measurements in nine healthy cats is shaded grey (50% hemolysis 
in NaCl 0.50–0.57% w/v) [10]. RBC OF significantly changed during 
the course of infection in cats in group A (pF = 0.0004, significantly 
higher levels at days 21 and 100 pi compared with day 0 pre‑inocula‑
tion, pD < 0.05), but not in cats in group B.
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higher in group A compared to group B during the 
study period, but significance was not achieved. The 
eosinophils showed a similar pattern to the lymphocyte 
counts in cats in group A, but the decrease in cell counts 
was delayed, and the nadir was reached at 6  weeks pi 
(pF < 0.0001, Figure 5B); again, this pattern was less pro-
nounced in cats in group B (pF = 0.0067, Figure 5B). In 
contrast, the monocyte counts increased after infection 
in cats in group A, with maximal values reached at day 
35 pi (pF < 0.0001, Figure 5C); again, this pattern was less 
pronounced in cats in group B (pF = 0.0135, Figure 5C). 
When compared to the counts in group B, the monocyte 
counts in group A were higher at most of the time points 
pi, with significance reached at days 3, 21, 35, and 100 
pi (pMWU  <  0.05, Figure  5C). The monocyte cell counts 
were higher in group A compared to group B at most 
time points pi when cat JHW3 was excluded, with sig-
nificance reached at days 3 and 21 pi (PMWU < 0.05). The 
neutrophils significantly changed over time only in cats 
in group A (pF = 0.0007, Figure 5D). There were no sig-
nificant differences in the neutrophil counts between the 
two groups.
When the course of the different white blood cell sub-
sets was compared with the course of PCV and Mhf 
bacteremia, most cats showed a decrease in the leuko-
cyte, lymphocyte, and neutrophil cell counts just prior 
to the decrease in PCV and the onset of maximal Mhf 
blood loads (data not shown). A similar pattern was also 
observed for the eosinophils, whereas the monocyte 
counts peaked at the onset of maximal anemia in most of 
the cats (data not shown).
Higher B lymphocytes in passively immunized than in 
control cats
In the passively immunized cats, all analyzed lymphocyte 
subsets [CD5+, CD4+ and CD8+ T lymphocytes, acti-
vated CD4+ T lymphocytes (CD4+CD25+) and B lym-
phocytes (CD45R/B220+)], showed a significant change 
over time (pF  <  0.05). In the control cats, a significant 
change during the course of infection was only observed 
for the activated CD4+ T lymphocyte subset (pF < 0.05). 
Specifically, cats in group A showed a significant decrease 
in the CD4+, CD8+ and CD5+ T lymphocyte counts, with 
the nadir reached at days 21, 21 and 28 pi, respectively, 
coinciding with the onset of peak bacteremia (CD4+, 
pF  =  0.0012; CD8+, pF  =  0.0002; CD5+, pF  <  0.0002, 
Figures  6A–C). The CD4+/CD8+ ratio was significantly 
increased at 2–3  weeks pi in the passively immunized 
cats (pF =  0.0002, Figure  6D). Cats in group A showed 
a significant decrease in their B lymphocyte counts dur-
ing maximal bacteremia, with the nadir reached at day 28 
pi (pF = 0.0103, Figure 6E), and the B lymphocyte counts 
were significantly higher at days 3, 14, 42 and 98 pi 
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Figure 5 Lymphocyte, eosinophil, monocyte and neutrophil 
counts during the course of Mhf infection. Mean (±SD) abso‑
lute cell counts of lymphocytes (A), eosinophils (B), monocytes (C) 
and neutrophils (D) during the 100‑day pi period in group A (black 
dots, solid line) and group B (open triangles, dashed line). Cats were 
subcutaneously inoculated with Mhf at day 0. The onset of bacteremia 
(day 7 pi for both groups) is indicated with a triangle. Boxes represent 
the time of peak bacteremia in cats in group A (grey box) and group B 
(dotted box). Statistically significant differences between groups A and 
B are indicated with asterisks (pMWU < 0.05). A Lymphocyte cell counts 
changed significantly over time in group A (pF < 0.0001; lower at days 
17, 21, 24 and 28 pi compared with days 3, 63 and 70 pi, pD < 0.05) and 
group B (pF = 0.0033, no significance in the posttest). B Eosinophil cell 
counts changed significantly over time in group A (pF < 0.0001, lower 
at days 38, 42, 49, 56 and 63 pi compared with day 0 and days 3, 7, 10, 
14, 84 and 98 pi, pD < 0.05) and group B (pF = 0.0067, no significance in 
the posttest). C Monocyte cell counts changed significantly over time 
in group A (pF < 0.0001, higher at days 3, 7, 14, 17, 21, 24, 31, 35, 38 and 
49 pi compared with days 84, 91, 98 and 100 pi, pD < 0.05) and group B 
(pF = 0.0135, no significance in the posttest). D Neutrophil cell counts 
changed over time only in group A (pF = 0.0007, no significance in the 
posttest).
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compared with cats in group B (pMWU < 0.05; Figure 6E). 
When cat JHW3 was excluded from the analyses, the B 
lymphocyte counts were also higher in cats in group A 
compared to cats in group B, with significance reached 
at days 3 and 14 pi (PMWU  <  0.05). The activated CD4+ 
T lymphocyte subsets showed a somewhat different pat-
tern than the other lymphocyte subsets in group A. The 
activated CD4+ T lymphocyte counts increased early 
during the course of infection into the onset of PCR-
positivity and peak bacteremia, and then, they markedly 
decreased and reached a nadir at day 42 pi (pF < 0.0001); 
this pattern was also present but less pronounced in 
group B (pF  =  0.0249, Figure  6F). Furthermore, com-
pared with cats in group B, cats in group A showed sig-
nificantly higher activated CD4+ T lymphocyte counts 
at day 14 pi (pMWU  =  0.0400) and significantly lower 
levels at day 42 pi (pMWU  =  0.0193; Figure  6F). When 
cat JHW3 was excluded from the analyses, a tendency 
for higher activated CD4+ T lymphocyte counts in cats 
in group A compared to group B was found at day 14 pi 
(PMWU = 0.0539); the difference at day 42 pi was still sig-
nificant (lower counts in cats in group A when compared 
to cats in group B; PMWU = 0.024).
Compared to control cats, passively immunized cats had 
higher bilirubin, total protein and globulin levels
Bilirubin concentrations significantly increased in 
both groups during the course of the experiment and 
peaked at day 49 pi (group A, pF  <  0.0001; group B, 
pF  =  0.0036; Additional file  1A). Bilirubin concentra-
tions were lower in group A than in group B at days 0 
and 14 pi (pMWU =  0.04) but tended to be higher from 
day 28 until the end of the experiment, with signifi-
cance reached at day 91 pi (pMWU =  0.0080; Additional 
file  1A). The mean bilirubin concentrations in both 
groups remained within the reference interval (bilirubin 
concentration <3.5 μmol/L) throughout the study period; 
bilirubin concentrations exceeding the reference interval 
were observed in three cats in group A (DHR 1, day 49 
pi, JHW1, day 49 pi; JHW5, day 56 pi, bilirubin concen-
trations, range 4.4–7.7  μmol/L). The total protein con-
centrations significantly changed over time in groups A 
(pF < 0.0001) and B (pF = 0.0003; Additional file 1B) and 
peaked at days 63 and 42 pi, respectively. Higher total 
protein concentrations were observed in cats in group A 
compared to cats in group B, with significance reached 
at days 21, 35 and 49 pi (pMWU  =  0.0400; Additional 
file 1B). When cat JHW3 was excluded from the analyses, 
total protein concentrations of group A were also higher 
compared to cats in group B with significance reached at 
days 3, 21 and 42 pi (PMWU < 0.05). The mean total pro-
tein concentrations of both groups remained within the 
reference interval (total protein, reference interval for 
16–30  weeks of age, 33–75  g/L) throughout the study 
period; total protein concentrations above the reference 
interval were observed in two cats in group A and one 
cat in group B (total protein concentrations between 
76.2–78.6 g/L). The globulin concentrations significantly 
increased over time only in group A (pF < 0.0001; Addi-
tional file  1C). Compared with cats in group B, cats in 
group A showed significantly higher globulin concen-
trations at days 21 and 35 pi (pMWU  <  0.05; Additional 
file 1C).
Discussion
This is the first study to investigate the protective role 
of the humoral immune response against hemoplasma 
infection using a passive immunization experiment. Our 
study demonstrated that the passive transfer of antibod-
ies from Mhf-recovered to naïve SPF cats does not pre-
vent infection, high bacterial loads and the development 
of clinical signs following homologous challenge with 
Mhf. The passively immunized and control cats showed 
no differences in the onset and extent of bacteremia and 
anemia during the course of Mhf infection. Hicks et  al. 
[28] recently documented that Mhf-recovered cats were 
protected from reinfection following re-challenge with 
a homologous Mhf isolate. Our study indicates that the 
presence of antibodies to Mhf cannot mediate protection 
against homologous challenge, but that cellular or innate 
immune mechanisms may be necessary to provide pro-
tection against Mhf infection. This is also in line with the 
study by Hicks et al. [28], which reported protection from 
Mhf reinfection in the absence of a pronounced Th2-type 
response in the cats after re-challenge. In the latter study, 
the protected cats showed no increase in anti-DnaK anti-
body and IL-10 mRNA levels following Mhf re-challenge.
The anti-DnaK antibody levels in the passively immu-
nized cats were only higher in the first 2  weeks after 
transfusion than in the control cats, and they remained 
below the threshold for seropositivity up to day 28 pi. 
It is possible that the level of antibodies in the passively 
immunized cats following transfusion was not sufficiently 
high to prevent bacteremia. However, Hicks et  al. [28] 
documented protection from Mhf although the antibody 
levels to DnaK did not rise after Mhf challenge infection 
and remained at rather low levels (mean log-transformed 
relative antibody level (RAL)  <  1.2) when compared to 
the control cats with de novo Mhf infection (peak mean 
RAL > 2.2). They concluded that if Mhf-specific antibod-
ies had been responsible for immune protection in these 
cats, then low levels of anti-DnaK antibodies could be 
sufficient to provide protection against Mhf infection. 
Because the assay and the calculations used to quantify 
anti-DnaK antibodies in that study were different from 
those used in the present study, a direct comparison of 
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antibody titers was not possible. Furthermore, it needs to 
be considered that antibodies with different epitope spe-
cificities that are not detected with current DnaK ELISA 
could mediate immune protection. However, assays to 
measure such antibodies are not available.
Infection enhancement, i.e. earlier onset of bacteremia 
and anemia, was recently documented in cats that had 
recovered from CMt infection and were re-challenged 
with Mhf [15]. All CMt-recovered cats were serologi-
cally positive before Mhf inoculation. The study suggested 
that the pre-existing antibodies against CMt might have 
had enhanced infection kinetics in the CMt-recovered 
cats [15]. Although infection kinetics were not different 
between the passively immunized and control cats in this 
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Figure 6 CD4+, CD8+ and CD5+ T lymphocytes, B lymphocytes and activated CD4+ T lymphocytes during the course of Mhf infec-
tion. Mean (±SD) cell counts of the CD4+ (A), CD8+ (B) and CD5+ T lymphocytes (C), CD4+/CD8+ ratio (D), B lymphocytes (CD45R/B220+, E) and 
activated CD4+ T lymphocytes (CD4+CD25+, F) at day 0 and during the 100‑day pi period in group A (black dots, solid line) and group B (open 
triangles, dashed line). Cats were subcutaneously inoculated with Mhf at day 0. The onset of bacteremia in group A and B (day 7 pi, both groups) 
is indicated with a triangle. Boxes represent the time of peak bacteremia in group A (grey box) and B (dotted box). Statistically significant differ‑
ences between group A and B are indicated with asterisks (pMWU < 0.05). A CD4
+ T lymphocyte counts changed significantly over time in group 
A (pF = 0.0012, lower at day 21 pi compared with days 3, 70 and 98 pi, pD < 0.05). B CD8+ T lymphocyte counts changed significantly over time 
in group A (pF = 0.0002; lower at day 21 pi compared with days 3, 70 and 98 pi, pD < 0.05). C CD5+ T lymphocyte counts changed significant over 
time in group A (pF < 0.0002, lower at day 21 pi compared with days 3, 70 and 98 pi, pD < 0.05). D CD4
+/CD8+ ratio changed significantly over 
time in group A (pF = 0.0002, lower at days 14 and 21 pi compared with day 0 and day 98 pi, pD < 0.05). E B lymphocyte counts changed signifi‑
cantly over time in group A (pF = 0.0103, lower at day 21 pi compared with day 3 pi, pD < 0.05). F Activated CD4+ T lymphocyte counts changed 
significantly over time in group A (pF < 0.0001, higher at days 3, 14 and 21 pi when compared with days 42, 56, 70 and 98 pi, pD < 0.05) and group B 
(pF = 0.0249, no significance in the posttest).
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study, our results still suggest that the transfer of antibod-
ies from Mhf-recovered cats could potentially be harm-
ful. The passively immunized cats showed a significant 
increase in RBC OF during the course of infection. This 
effect was not observed in the control cats, indicating that 
the increase was not simply due to a non-specific effect 
of plasma transfusion on RBC fragility. It can be hypoth-
esized that the antibodies bound to the Mhf organisms 
attached to RBCs. RBC-bound antibodies have been found 
after primary Mhf infection [16, 39, 40] and can induce 
receptor-mediated RBC phagocytosis or the activation of 
the complement system [41]. In the present study, RBC-
bound antibodies were not detected in the cats by Coombs 
test, but the sensitivity of this assay may be limited [42]. 
The bilirubin concentrations were also higher in the pas-
sively immunized versus control cats at some time points 
during infection. RBC destruction leads to the formation 
of free hemoglobin, which is processed by the mononu-
clear phagocytic system. During this process, bilirubin is 
formed, released in the blood stream and further metabo-
lized and excreted by the liver. During pronounced RBC 
destruction, the capacity of the liver to metabolize bili-
rubin is overwhelmed, and hyperbilirubinemia occurs. 
Hyperbilirubinemia was observed in three cats of group 
A, although mean bilirubin concentrations in both groups 
remained within the reference interval. Nevertheless, the 
higher RBC OF values and occasionally higher bilirubin 
concentrations could point towards a more pronounced 
RBC destruction in the passively immunized cats follow-
ing subsequent Mhf challenge exposure.
The passively immunized cats showed signs of a more 
pronounced immune response when compared to control 
cats. Cats of group A showed higher lymphocyte, mono-
cyte and B lymphocyte counts and higher total protein 
and globulin concentrations than the control cats at sev-
eral time points during the experiment. Furthermore, peak 
globulin concentrations coincided with peak anti-DnaK 
antibody levels in both groups. This result was also found 
in our recent study, where we documented polyclonal 
hypergammaglobulinemia during Mhf infection coinciding 
with high anti-DnaK antibodies [15]. We speculated that a 
large portion of the immune globulin pool was not hemo-
plasma-specific and was potentially due to a polyclonal B 
lymphocyte activation. The induction of autoreactive anti-
bodies has recently been reported for the porcine hemo-
plasma Mycoplasma suis and is thought to be caused by 
the upregulation of B lymphocytes in response to changes 
to the RBC surface of the infected host [43].
It could be argued that the use of the homologous Mhf 
isolate for experimental challenge of the recipient cats 
that had been used to infect the plasma donor cats con-
tributed to the more pronounced immune response in 
the passively immunized cats. This has been reported 
for other feline pathogens, i.e. feline coronavirus (FCoV) 
which can cause feline infectious peritonitis (FIP) [44]. 
During the pathogenesis of FIP, the virus targets mac-
rophages and infection of these cells can be enhanced in 
the presence of antibodies (antibody-dependent enhance-
ment, ADE) [45]. Takano et al. [44] showed that cats pas-
sively immunized with antibodies to serotype I FCoV 
showed an enhanced onset of disease following inocula-
tion with the homologous serotype; this was not found 
when cats passively immunized with antibodies to sero-
type II FCoV were challenged with serotype I. The authors 
concluded that FCoV re-infection with the same serotype 
might induce ADE and could advance the development 
of FIP. Although ADE has also been suspected in bacte-
rial infection [46], it is unknown whether it might play a 
role in the pathogenesis of feline hemoplasma infections 
[15]. Signs of infection enhancement have recently been 
documented in “Candidatus M. turicensis”-recovered, 
seropositive cats following a challenge with Mhf [15]. The 
study suggested that the presence of antibodies directed 
against CMt could enhance Mhf infection. However, to 
the best of our knowledge, disease enhancement after re-
challenge with the same feline hemoplasma species has 
not been documented. In contrast, two studies showed 
that cats that had recovered from Mhf or CMt infection 
were protected from re-infection following re-challenge 
with the same hemoplasma species, respectively [27, 28]. 
Both studies had used an aliquot of the same Mhf or CMt 
isolate for re-infection that had been used for primary 
infection of the cats (personal communication, RHL).
The passively immunized cats showed a significant 
decrease in lymphocyte counts near the onset of peak bac-
teremia (around 3 weeks pi). This comprised decreases in 
absolute counts of CD4+ T lymphocytes, CD8+ T lym-
phocytes and B lymphocytes around three to 4 weeks pi, 
and was followed by an increase of the lymphocyte sub-
sets until the end of the study. In two recent studies we 
reported a very similar pattern in the lymphocyte subsets 
following Mhf infection of naïve and CMt-recovered cats. 
The decrease was explained by the migration of the cells 
from the peripheral blood to the draining lymph nodes, 
where they become activated and proliferate [15, 28].
In the individual cats, the decrease in leukocyte, lym-
phocyte and neutrophil counts occurred just prior to the 
development of anemia and the onset of peak bactere-
mia. A similar pattern was also observed for the eosino-
phils, whereas the monocyte counts peaked at the onset 
of maximal anemia. A decrease in leukocyte and neutro-
phil counts could be caused by the increased consump-
tion of these cells, which are involved in bacterial killing 
or, less likely, by reduced production due to undefined 
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inhibitory factors [47]. Monocytosis could be found due 
to hemolysis [48] and was shown to be associated with 
Mhf infection in naturally infected cats [49]. We docu-
mented leukopenia and neutropenia, as well as decreased 
eosinophils, lymphocytes and increased monocytes, at 
times of peak Mhf bacteremia also in a recent study [15]. 
It is difficult to judge whether the decrease in the white 
blood cell subsets was due to bacterial replication and 
cell consumption or, conversely, whether the decrease in 
white blood cells facilitated bacterial replication.
Interestingly, one cat in group B (JHW3) stayed PCR-
negative and seronegative during the 100-day follow-up 
period, but it developed bacteremia and seroconverted 
154  days after Mhf inoculation. Although low-level bac-
teremia, below the detection limit of the PCR assay, can-
not be completely excluded in this cat, we would expect a 
productive infection to result in seroconversion [20, 50]. 
Because all cats in this study were kept under strictly con-
trolled hygienic conditions, vector-borne transmission 
between the cats can be excluded. However, all cats of 
group B were housed together and four out of five cats in 
group B tested Mhf PCR-positive at the time that bactere-
mia and seroconversion occurred in cat JHW3. Therefore, 
direct transmission between the cats, i.e., by aggressive 
interactions, seems most likely, although no obvious clini-
cal signs of aggressive interactions were observed in the 
cats in this study at any time during the experiment. A 
direct transmission of Mhf through saliva seems unlikely 
because only low hemoplasma loads can be detected in 
saliva of Mhf-infected cats [22] and transmission by oral 
or subcutaneous inoculation of saliva has not been suc-
cessful for another feline hemoplasma species, CMt [19].
The present study had some limitations. No masking 
was used during data collection and analysis. Further-
more, the relatively small groups size used in this study 
for animal welfare reasons could have masked signifi-
cant differences between the passively immunized and 
control cats. However, as no protection but rather signs 
of infection enhancement were found in the passively 
immunized cats, the limited group size should not have 
affected the principal hypothesis addressed in this study.
The present study used an experimental set-up to 
address the protective role of passively transferred anti-
bodies in Mhf infection. Experimental infection stud-
ies do have some inherent limitations when results are 
generalized to natural infections. However, to mirror the 
natural transmission of hemoplasmas most accurately, a 
published low-dose infection model was applied in this 
study [22]. The inoculated dose contained only 1000 cop-
ies of Mhf, which corresponds to approximately 0.05 μL 
of infectious blood from a naturally infected cat [22]. This 
small blood volume can easily be transmitted by blood-
sucking arthropods or via aggressive interaction between 
cats—both of the latter transmission routes are assumed 
to be natural ways of transmission for feline hemoplas-
mas [17–19]. Therefore, the infectious dose applied to the 
cats should not be the reason for the lack of protection in 
the passively immunized cats.
Several measures were undertaken to ensure that the 
plasma used for passive immunization did not contain 
viable Mhf organisms that could transmit infection. The 
donor cats were tested weekly for at least eight consecu-
tive weeks before the plasma was collected. All these 
samples and the plasma pool itself were tested in tripli-
cate with a highly sensitive Mhf-specific qPCR assay [12] 
and revealed PCR-negative results. Furthermore, an ali-
quot of the plasma pool used for passive immunization 
was transfused into an adult SPF, the cat was followed for 
23 weeks after transfusion and stayed PCR-negative.
In conclusion, passive immunization did not provide 
protection against experimental infection with Mhf but 
instead enhanced RBC fragility and was associated with a 
more pronounced immune response after infection. This 
result suggests that a humoral immune response in the 
absence of cellular immune mechanisms is insufficient 
to provide protection from Mhf infection. Potential vac-
cine candidates should include the induction of a cellular 
immune response against Mhf.
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